Why is Concord Drugs falling/rising?

As of 24-Jul, Concord Drugs Ltd is experiencing a decline in its stock price, currently at 56.11, reflecting a decrease of 1.14 or 1.99%. The stock has been underperforming, having fallen for the last eight consecutive days, resulting in a total decline of 16.25% during this period. Although the stock has shown impressive returns over the longer term, with a 48.99% increase over the past year, it has also faced challenges, including a 13% drop in profits. The stock is currently trading at a discount compared to its peers, which may indicate an attractive valuation despite recent price movements. Additionally, while the stock's moving averages are higher than the 20, 50, 100, and 200-day averages, it is lower than the 5-day moving average, suggesting a short-term weakness.
In the broader market context, Concord Drugs has significantly outperformed the benchmark Sensex over the past year, which has only increased by 2.54%. However, in the short term, the stock has underperformed its sector by 2.34%. The recent decline in stock price, despite rising investor participation indicated by a 7.13% increase in delivery volume, suggests that market sentiment may be cautious due to the consecutive losses and falling profits. Overall, while the long-term performance remains strong, the recent downturn reflects immediate investor concerns and market dynamics that are affecting Concord Drugs Ltd.